Explore the latest developments concerning A higher-dose flu.
A higher-dose flu shot could spare millions of older adults a hospital stay
This article has been reviewed according to Science X's
editorial process
and policies.
Editors have highlighted
the following attributes while ensuring the content's credibility:
Influenza is a seasonal condition that causes coughing, sneezing, mild fever and aches in most cases. However, it can sometimes take a serious turn, leading to hospitalization, especially for young children, adults over 65 and pregnant people. A recent study published in JAMA Network Open examined whether the high-dose inactivated influenza vaccine (HD-IIV), which contains four times as much antigen as the standard dose, offers superior protection against hospitalization and death.
Researchers analyzed data from eight large-scale clinical trials involving more than 600,000 participants that compared a high-dose flu shot with the standard flu shot in older adults.
People who received flu shots 40% less likely to test positive for influenza, new data show
A new study finds that flu shots were associated with moderate protection against the virus during the 2024-25 flu season.
People vaccinated against influenza that season were 40% less likely to test positive for flu than unvaccinated people, according to a study of more than 1.1 million Californians.
Adults aged 65 and older who tested positive for flu were 29% less likely to die of an influenza-related cause if they had received the vaccine, according to the study, published yesterday in JAMA Network Open. The study included flu-related deaths within 30 days of testing.
“These findings are consistent with protection against severe and fatal influenza among people vaccinated against influenza,” the study authors wrote.
myoslim Body Sculpting Machine Shaping 15 Teslas 6500W myoslim Radio Frequency RF Muscle Stimulator Device
High-Dose Flu Shot Beats Standard Dose in Older Adults
Among older adults, high-dose inactivated influenza vaccine (HD-IIV) was associated with lower risks for hospitalizations for influenza, laboratory-confirmed influenza, pneumonia or influenza, cardiorespiratory disease, and all causes than standard-dose IIV (SD-IIV).
“Overall, these findings demonstrate the clinical benefits of HD-IIV in lowering hospitalization risk, underscoring its value in reducing influenza burden among older adults and the corresponding impact across health systems,” the authors wrote.
“These findings may inform decision-makers in developing vaccine recommendations and policies,” they added.
The study was led by Kristoffer Grundtvig Skaarup, MD, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark. It was published online on May 26, 2026, in JAMA Network Open.
For more detailed information, explore updates concerning A higher-dose flu.
0 Comments